Title of article
Essential Thrombocythemia Following Immune Thrombocytopenia With JAK2 V617F Mutation: A Case Report
Author/Authors
Payandeh ، Mehrdad Department of Hematology and Medical Oncology - Kermanshah University of Medical Sciences , Aeinfar ، Mehrnoush Medical Biology Research Center - Kermanshah University of Medical Sciences , Dadashizadeh ، Kimiya Department of Biology - Faculty of Science - University of Maragheh , Yari ، Saba Department of Biology - Faculty of Science - University of Maragheh
From page
141
To page
144
Abstract
Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder. Tyrosine Kinase JAK2 (JAK2 V617F) mutation occurs in nearly 60% of Essential Thrombocythemia (ET) patients. Both diseases produce impaired platelet. We describe a case with ET following ITP. So far, only 3 reports described ET following ITP. We report the fourth patient with JAK2 V617F mutation at the onset of ITP presented 20 years ago that needed splenectomy. The association of these two diseases may recommend similar pathogenic mechanisms between Myeloproliferative Neoplasms (MPNs) and ITP that should be further explored.
Keywords
Jak2 mutation , Essential thrombocythemia , Immune thrombocytopenia
Journal title
Case Reports in Clinical Practice
Journal title
Case Reports in Clinical Practice
Record number
2696163
Link To Document